Karen Baxter, former VP & GM at Dexcom with deep expertise in diabetes device commercialization across Europe, joins as SVP Sales, Europe Jay Little, leader from Medtronic Diabetes, appointed VP Strategy & Business Development Team expansion will drive growth strategy, market development, and partnerships for scalable expansion to accelerate Kaleido’s growth across European markets Utrecht, […]
Last week, Optimum hosted its 17th Annual Healthcare Investor Conference 2025. Held in the heart of London, the event brought together a powerhouse of industry leaders, investors, innovators, and communicators to exchange ideas, explore the market outlook, and tackle the pressing questions facing the life sciences sector. If you missed the day, or just want […]
Brings over 35 years of oncology drug development experience, including senior executive leadership roles at AstraZeneca and Daiichi Sankyo Led the development and approval of multiple breakthrough medicines such as ENHERTU®, TAGRISSO®, and LYNPARZA® Strengthens Ona’s transition to a clinical-stage company with ONA-255, while advancing its pipeline of first-in-class ADCs targeting major solid tumors Barcelona, […]
AMSilk Secures EUR 52M Strategic Financing to Accelerate Commercial Growth AMSilk GmbH has successfully secured EUR 52 million financing led by existing investor ATHOS (AT Newtec), along with strong participation from fellow existing investors MIG Capital and Novo Holdings. The financing will enable AMSilk to scale industrial production and meet global customer demand for its […]
Novo Holdings and the Export and Investment Fund of Denmark (EIFO) have jointly invested €48 million in HealthCap IX, a Swedish life sciences venture fund focused on building innovative companies in areas of high unmet medical need. Following the investment, HealthCap will establish a local presence in Copenhagen at the BioInnovation Institute (BII) to increase […]
